testosterone

In the middle of the twentieth century, doctors explored hormone treatments for various conditions linked to aging. One area of interest was senile pruritus and senile eczema, terms used at the time for intense itching and skin inflammation that often affected older people. Researchers noticed that these problems sometimes appeared alongside declining hormone levels, particularly in men. This led to small experiments with testosterone as a possible remedy.

A notable report came in 1945 from doctors William L. Dobes, Jack Jones, and Andrew G. Franks at Emory University. They published their findings in The Journal of Clinical Endocrinology & Metabolism. The team worked with ten patients who had senile pruritus, a condition marked by severe, widespread itching and sometimes skin changes resembling eczema. The patients received testosterone propionate through injections, local skin applications, and oral methyl testosterone.

According to the doctors, the treatment brought noticeable relief for many in the group. Itching decreased and skin symptoms improved in a good number of cases, especially when the issues seemed tied to age-related hormone decline. One example mentioned involved a patient whose pruritus and dermatitis came under control with testosterone after vitamins had not helped. The results were presented as promising for this specific type of age-related skin complaint.

These early observations fit with the idea that testosterone can influence the immune system. Modern understanding shows that testosterone tends to suppress Th2 immune responses, the type often overactive in atopic eczema and allergic skin conditions. By calming this pathway, the hormone could in theory reduce inflammation and itching. However, the 1940s work was not a large or tightly controlled clinical trial by today's standards. It involved only a handful of patients, lacked placebo comparisons, and focused mainly on older adults with senile forms of skin trouble rather than common atopic eczema seen in children or younger adults.

Later medical research has not turned testosterone into a standard treatment for eczema. Some studies have looked at hormone levels in people with atopic dermatitis and explored how testosterone might affect skin barrier function or inflammation, but results remain mixed. While it may help certain inflammatory aspects, there are also concerns that androgens can sometimes affect skin thickness or oil production in ways that are not always beneficial. No large-scale modern trials have established testosterone as a safe or effective option for routine eczema care.

The historical use of testosterone for senile pruritus and eczema reflects an era when doctors were just beginning to connect hormones with skin health and aging. Those small studies from the 1940s reported positive outcomes in relieving symptoms for many participants, yet they stayed limited in scope. Today, eczema management relies on moisturizers, topical steroids, newer anti-inflammatory creams, and other targeted therapies. The old experiments with testosterone serve mainly as an interesting footnote in medical history, highlighting how hormone balance can play a role in skin conditions.

(Source : Grok)

The Male Hormonal Shield: Testosterone’s Role in Dampening Allergic Inflammation

Sex steroid hormones have a profound influence on the immune system, and the relationship between testosterone and the arm of adaptive immunity governed by T helper 2 (Th2) cells is a particularly clear example of this regulation. Far from simply being a reproductive chemical, testosterone acts as a general suppressor of the immune system, and its effects are especially potent against the type of inflammation driven by Th2 cells. This interaction is a key biological reason why, after puberty, many allergic and Th2-dominated conditions such as asthma become significantly more common and severe in females than in males.

The primary effect of testosterone on a Th2-driven response is one of powerful suppression. The hormone works to actively dampen the entire inflammatory cascade. In animal models of allergic airway inflammation, a classic Th2-mediated disease, the presence of testosterone leads to a direct decrease in the accumulation of immune cells like eosinophils and neutrophils in the lungs. It also reduces the production of IgE antibodies and lessens airway hyperresponsiveness, the tendency of the airways to constrict too easily. Underlying these whole-body responses, testosterone decreases the number of Th2 cells in the lung that are actively producing the signature type 2 cytokine, IL-13, and reduces the production of other key Th2 cytokines such as IL-4 and IL-5. This suppressive effect is not limited to adaptive immunity; testosterone also acts on the innate arm of the immune system by potently inhibiting the proliferation and function of group 2 innate lymphoid cells (ILC2s), an early source of the same type 2 cytokines that shape the subsequent Th2 response.

The mechanism behind this suppression is multi-layered, involving direct molecular signaling and indirect cellular crosstalk. The most definitive pathway occurs when testosterone, or its more potent metabolite dihydrotestosterone (DHT), binds directly to the androgen receptor inside a naive T cell that is destined to become a Th2 cell. This hormone-receptor complex then moves to the cell’s nucleus and acts as a transcription factor, directly turning on the gene that encodes a protein called dual-specificity phosphatase 2 (DUSP-2). DUSP-2 is a negative regulator of the p38 MAP kinase signaling pathway, which is critical for the optimal production of Th2 cytokines. By boosting DUSP-2 levels, testosterone undermines the cell’s molecular machinery, preventing it from producing large amounts of the characteristic Th2 proteins. This direct signaling route is so central that in experiments where the androgen receptor is genetically deleted only from T cells, androgen treatment can no longer suppress Th2 cytokine production, and the animals develop a much more severe form of allergic inflammation.

In a parallel mechanism, testosterone also influences the Th2 response indirectly by first acting on other cell types. For instance, androgen signaling within the same T cell population can also suppress the development of Th17 cells. Th17 cells are not Th2 cells, but they produce IL-17A, a cytokine that is often elevated alongside Th2 cytokines in severe asthma and can exacerbate tissue inflammation. By suppressing the Th17 pathway, testosterone helps restructure the overall inflammatory environment into a less aggressive state. Furthermore, a crucial indirect path involves IL-4, the master cytokine that drives Th2 cell differentiation. Testosterone signaling through the androgen receptor has been shown to suppress the initial production of IL-4 from innate sources during an allergic reaction, which in turn leads to a secondary decrease in the number of IL-13-producing Th2 cells in the affected tissue. In this way, testosterone can tamp down the Th2 response without the androgen receptor ever needing to be activated inside the Th2 cell itself.

The clinical relevance of this androgen-Th2 interaction is most vividly illustrated by the sex disparity in diseases like asthma. Before puberty, the prevalence of asthma is higher in boys than girls, but this ratio reverses dramatically after adolescence, when adult women become about twice as likely to have asthma as men. This switch correlates with the rise in testosterone levels in males, which provides a protective effect against the Th2/ILC2-driven allergic inflammation in the lungs. In contrast, female sex hormones like estrogen tend to enhance Th2 responses. Therefore, testosterone is not just a bystander in Th2 immunity but a central regulator whose molecular actions—primarily the upregulation of DUSP-2 at the genomic level and the broader suppression of cytokine networks—explain why the male immune system is often biased away from developing potent and potentially harmful type 2 inflammatory responses.

How Testosterone Silences the Early Alarm: Epithelial Cells, Tregs, and the Th2 Axis

There are a few additional layers to this interaction that are worth noting, as they help to complete the picture of how testosterone shapes Th2-driven inflammation in real-world biology.

A significant part of the story involves the very earliest triggers of a type 2 immune response. The epithelial cells that line the airways, skin, and gut are the first to encounter allergens and parasites. When damaged or irritated, these cells release alarmin cytokines, particularly IL-33, TSLP, and IL-25, which act as a wake-up call to the immune system by activating ILC2s and setting the stage for a robust Th2 response. Testosterone and DHT signaling through the androgen receptor have been shown to suppress the release of these alarmins from airway epithelial cells. This means that before a Th2 cell even gets involved, testosterone is already working at the barrier surface to raise the threshold for initiating the entire allergic inflammatory cascade. By reducing the IL-33 that normally fuels ILC2s, testosterone indirectly starves the developmental path that leads to a dominant Th2 response.

Another nuance concerns the balance of T cell subtypes beyond the straightforward suppression of Th2 cells. Androgen signaling can also tilt the immune system toward tolerance by influencing regulatory T cells (Tregs). In some contexts, testosterone promotes the function and stability of Tregs, the cells responsible for calming down immune reactions and preventing excessive inflammation. A more active Treg compartment naturally restrains the expansion and activity of Th2 cells in mucosal tissues. This effect complements the direct DUSP-2 mechanism: the hormone not only makes it harder for a developing Th2 cell to produce its cytokines, but it simultaneously strengthens the suppressive network that keeps that cell in check.

The clinical picture extends beyond asthma. A condition that powerfully illustrates the immune consequences of removing testosterone’s influence is androgen deprivation therapy, a common treatment for prostate cancer. Men receiving these treatments, which drastically lower testosterone levels, experience a notable increase in Th2-related conditions such as allergic rhinitis and new-onset asthma. Their immune profiles shift toward higher levels of IgE and more pronounced eosinophilic inflammation. This human experiment of nature confirms that even in adulthood, the continuous presence of testosterone actively suppresses the Th2 axis. Conversely, in transgender men receiving masculinizing hormone therapy, reductions in Th2 biomarkers and improvements in pre-existing allergic symptoms have been observed, though research in this area is still growing.

Finally, it is important to remember that while testosterone broadly suppresses Th2 responses, its influence is part of a larger hormonal network. The final outcome of an immune challenge depends on the balance between testosterone and other hormones like progesterone and estradiol, as well as on local tissue concentrations of aromatase, the enzyme that converts testosterone to estradiol. This local conversion can create microenvironments where androgenic and estrogenic signals compete, adding a further layer of regulation that can differ from one organ to another. Nonetheless, the overarching theme remains consistent: testosterone, acting primarily through the androgen receptor to induce negative regulators like DUSP-2 and to dampen innate type 2 alarmins, serves as a critical brake on the development and severity of Th2-driven inflammation.

Testosterone: Shield Against Allergy, Gateway to Helminths

The discussion so far has focused on how testosterone suppresses Th2-driven inflammation in allergic disease, but there is another important dimension to this interaction that becomes clear when moving from allergy to infection. Th2 responses did not evolve to cause hay fever and asthma; they evolved to defend the body against large multicellular parasites, particularly helminth worms. In this context, testosterone’s suppressive effect on Th2 immunity represents a genuine biological trade-off, providing protection from allergic pathology while simultaneously increasing vulnerability to parasitic disease.

Across many mammalian species and in human populations, males consistently carry heavier burdens of intestinal worms and other helminths compared to females. This pattern is directly linked to the immunosuppressive action of androgens on the Th2 axis that would otherwise be responsible for expelling the parasites. In rodent models, castration of males leads to enhanced Th2 responses and more rapid worm clearance, while testosterone replacement restores susceptibility. The very same mechanisms that keep asthma in check, such as the reduction of IL-13, IL-4, and IL-5 production and the dampening of ILC2 activation, also impair the coordinated immune attack needed to expel worms from the gut or tissues. The testosterone-driven induction of molecules like DUSP-2 inside T cells, which serves as a brake on type 2 cytokine production, operates regardless of whether the antigen triggering the Th2 response is a harmless pollen grain or a life-threatening parasite.

This trade-off has real-world consequences. In regions where helminth infections are endemic, men often exhibit higher worm counts and a slower rate of spontaneous cure than women. This sex difference is most pronounced after puberty, exactly when testosterone levels diverge, and it fades again later in life as testosterone declines. So the effect of testosterone on Th2 biology is not simply a one-sided immunological handicap but a reshaping of the immune system that prioritizes resistance to certain classes of pathogens, such as intracellular bacteria and viruses driven by Th1 responses, at the expense of optimal defense against multicellular parasites. The Th2 suppression that spares males from many allergic conditions is the same force that can leave them more open to parasitic invasion, a classic evolutionary balance between protection and susceptibility.

(Source : DeepSeek)

Testosterone is a hormone that plays many important roles in the body, from driving physical development during puberty to maintaining muscle and bone strength throughout life. Despite its association with building and strengthening certain tissues, testosterone can have a very different effect on the skin, actually making it weaker over time. This may sound contradictory, but the process comes down to how the hormone interacts with the deep structural layers that give skin its resilience.

The skin’s strength and plumpness depend heavily on a meshwork of proteins, chiefly collagen and elastin, along with water-attracting molecules like hyaluronic acid. Collagen provides a sturdy scaffold, elastin allows the skin to stretch and snap back, and hyaluronic acid keeps everything hydrated and cushioned. When this support system is compromised, the skin becomes thinner, less elastic, and more fragile. Testosterone can interfere with all three of these critical components.

Deep within the dermis, the skin’s middle layer, special cells called fibroblasts are responsible for producing new collagen and elastin. These fibroblasts have docking stations, known as androgen receptors, that allow testosterone and related hormones to attach and send signals. When testosterone levels are high, the signals can dial down the fibroblasts’ activity. The cells begin to manufacture less procollagen, the raw material that gets woven into mature collagen fibers. At the same time, the hormone can ramp up the production of enzymes called matrix metalloproteinases, whose job is to break down existing collagen and elastin. The net result is a slower build rate and a faster demolition rate, leaving the skin’s scaffolding increasingly sparse and disorganized.

The impact does not stop with protein fibers. Testosterone also influences the skin’s water-holding capacity. Hyaluronic acid, which binds moisture and gives skin its bounce, is partly regulated by hormonal signals. Under the influence of higher testosterone activity, the skin may retain less hyaluronic acid, leading to a loss of hydration and volume. A dehydrated, less padded dermis is naturally more prone to creasing and damage.

There is a notable difference in how male and female skin typically age, and this difference highlights testosterone’s weakening effect. Before menopause, women’s higher estrogen levels help stimulate collagen production and maintain skin thickness. Men’s skin, which is exposed to sustained testosterone throughout adulthood, gradually becomes thinner and loses collagen at a steady rate. In fact, by middle age, a man’s dermis is often significantly thinner than a woman’s of the same age, and this thinner skin is more susceptible to cuts, tears, and wrinkles. Similar patterns can be seen when people undergo hormone therapy that raises testosterone levels, with some noticing that their skin becomes less plump and more fragile.

Beyond direct structural changes, testosterone stimulates the sebaceous glands to produce more oil. While oil itself is not inherently weakening, an overproduction can alter the skin’s barrier function and lead to chronic inflammation through conditions like acne. Persistent low-grade inflammation can further degrade collagen and elastin over time, adding another subtle layer of damage to the skin’s framework.

The weakening effect is not an all-or-nothing response. It depends on how much testosterone is present, how sensitive an individual’s androgen receptors are, and what other hormones are in the mix. Still, the underlying biology is clear. Testosterone has the capacity to thin the skin by slowing collagen production, speeding up its breakdown, and reducing the natural moisturizing factors that keep the tissue supple and strong. This dual action, working beneath the surface over months and years, explains why the hormone that strengthens so many other parts of the body can quietly undermine the structural integrity of the skin.

There is more to the picture, particularly when looking deeper at how testosterone is processed by the skin itself and how it affects layers beyond the dermis. This adds important context about why the weakening effect can vary so much from person to person.

The skin is not a passive target for testosterone floating in the bloodstream. It contains an enzyme called five-alpha reductase that converts testosterone into a much more potent androgen called dihydrotestosterone, or DHT. DHT binds to the same androgen receptors on fibroblasts but with far greater strength and for a longer duration, amplifying the signal that slows collagen production and ramps up the activity of collagen-degrading enzymes. The level of this enzyme in an individual’s skin dictates how intensely the hormonal message is felt. Someone with highly active five-alpha reductase in their dermal cells may experience more pronounced thinning even with normal circulating testosterone levels. This local hormone processing means the weakening of skin is not simply a matter of how much testosterone the body makes but also of how the skin itself transforms it.

The influence of testosterone also extends upward into the epidermis, the outermost living layer, and downward into the fat layer that cushions the skin. In the epidermis, androgens can subtly reduce the rate of cell turnover and may lead to a slightly thinner, less robust protective barrier. A thinner epidermis is more easily breached by irritants and loses water more readily, which compounds the dryness already set in motion by the loss of hyaluronic acid deeper down. Beneath the dermis, in the subcutaneous fat, testosterone tends to reduce the size and number of fat cells over time. This layer of fat acts as a natural shock absorber and provides structural fullness. When it shrinks, the skin above it loses some of its underlying support, becoming more prone to wrinkling, sagging, and mechanical injury because there is less padding to buffer everyday bumps and pressure.

Another aspect worth understanding is the indirect effect testosterone exerts through the balance of other hormones. A portion of the body’s testosterone is normally converted into estradiol, a form of estrogen, via an enzyme called aromatase that is also present in the skin. Estrogen is a strong friend to the skin, promoting fibroblast activity, collagen synthesis, and hydration. When testosterone levels are high but the efficiency of aromatase is low, the skin loses this protective conversion and the weakening effect of androgens goes largely unopposed. This explains why, for example, during andropause when testosterone and its conversion to estrogen both decline, skin aging can accelerate for different hormonal reasons, while in younger individuals with high testosterone and low aromatase activity, the skin might still thin prematurely. The net condition of the skin often reflects the ratio of androgen activity to estrogen activity within the tissue rather than the absolute level of testosterone alone.

Finally, the structural weakening also becomes visible in how the skin repairs itself after injury. Testosterone has been shown to dampen the early inflammatory phase of wound healing and slow the migration of keratinocytes needed to close a wound. Combined with a leaner collagen mesh and a thinner epidermis, this means that skin under a strong androgenic influence not only sustains damage more easily but also rebuilds itself more slowly, lengthening the time that the area remains vulnerable. This healing delay is a practical consequence of the same underlying mechanisms that cause gradual thinning over the years.

(Source : DeepSeek)

On the heels of a large-scale clinical trial now underway to confirm that the female hormone estriol combats the effects of multiple sclerosis in women, a recently completed UCLA pilot study shows promise for the use of testosterone to combat the effects of the disease in men.

Reporting in the May issue of the journal Archives of Neurology, Dr. Rhonda Voskuhl, director of UCLA's Multiple Sclerosis Program, and her colleagues found that the application of a testosterone gel reduced symptoms, slowed brain degeneration and increased muscle mass in men with relapsing-remitting multiple sclerosis, the most common form of the disease. Testosterone also has been shown to protect against an MS-like condition in animals.

Multiple sclerosis is a progressive disease involving the immune and central nervous systems. Like many other autoimmune diseases, in which the body attacks its own systems or tissues, MS is less common in men than in women, said Voskuhl, with a ratio of about three women to one man. Voskuhl has long thought that sex hormones and/or sex chromosomes may be responsible for this enhanced susceptibility.

Voskuhl and Dr. Nancy L. Sicotte, UCLA assistant professor of neurology, conducted a study of testosterone treatment in 10 men with relapsing-remitting MS, which is characterized by periods of neurologic symptoms, such as numbness or difficulty walking, followed by periods of remission. After enrollment in the study, the men, whose average age was 46, entered a six-month pre-treatment phase, during which symptoms were monitored but no therapies were administered. After that, each man applied 10 grams of a gel containing 100 milligrams of testosterone to his upper arms once daily for 12 months.

"After a year, we saw an improvement in cognitive performance and a slowing of brain deterioration," Voskuhl said. In fact, during the final nine months of gel application, the rate of brain deterioration in the men slowed by 67 percent.

In addition, the men's muscle mass increased an average of 1.7 kilograms, about 3.74 pounds, during the treatment phase. There were no reported adverse effects.

"The other optimistic thing about this study was that the protective effect of testosterone treatment on brain atrophy was observed in the absence of an appreciable anti-inflammatory effect," said Voskuhl, "which suggests the protection the testosterone provided may not be limited to MS but may be applicable to other non-inflammatory neurodegenerative diseases, such as Parkinson's or Alzheimer's disease."

Four years ago, Voskuhl conducted a pilot study in which 10 women with MS were given the female hormone estriol, which yielded what she described as "pretty remarkable" results — an 80 percent drop in inflammatory lesions in the brain, which are a hallmark of the disease. That led to the much larger trial now underway. Her goal now is to expand the testosterone pilot study into a much larger clinical trial.

"Overall, the use of the testosterone gel treatment in men with MS was shown to be safe and well-tolerated," she said. "In addition, our exploratory findings suggest there's a possible neuroprotective effect of testosterone treatment in men, which we feel warrants a larger study."

The UCLA Department of Neurology encompasses more than a dozen research, clinical and teaching programs. These programs cover brain-mapping and neuroimaging, movement disorders, Alzheimer's disease, multiple sclerosis, neurogenetics, nerve and muscle disorders, epilepsy, neuro-oncology,

neurotology, neuropsychology, headaches and migraines, neurorehabilitation, and neurovascular disorders. The department ranked No. 1 among its peers nationwide in National Institutes of Health funding in 2005.

(Source : UclaHealth)